Clavulanic Acid

CHEMBL777 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

199.2 g/mol

LogP

-1.2

Phase

4

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Masse moléculaire

199,1600 g/mol

LogP

-1,20

TPSA

87,10 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Bladder Cancer Pain Management Asthma Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Infectious Disease Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Chronic Pain Tuberculosis Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Mécanisme d'action

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21

InChI

InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1

Molecular Formula

C8H9NO5

HBD / HBA

2 / 5

Liaisons Rotatives

2

Atomes Lourds

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL777. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5280980. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Clavulanic Acid sur PillFYI

Structure

Données Clés

Formule: C8H9NO5

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.